UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 128

Sortiert nach

Overview of current systemic management of EGFR-mutant NSCLC

Annals of oncology, 2018-01, Vol.29 (suppl_1), p.i3-i9

2018

Link zum Volltext

Verfügbarkeit prüfen

LBA1_PR Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts

Journal of thoracic oncology, 2016-04, Vol.11 (4), p.S152-S152

2016

Link zum Volltext

Verfügbarkeit prüfen

P0066 A randomised phase 3 study comparing first-line pemetrexed plus cisplatin followed by gefitinib as maintenance with gefitinib monotherapy in east Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer

European journal of cancer (1990), 2014-05, Vol.50, p.e27-e27

2014

Link zum Volltext

Verfügbarkeit prüfen

32 LUX-Lung 3: Symptom and health-related quality of life results from a randomized phase III study in 1st-line advanced NSCLC patients harbouring EGFR mutations

Lung cancer (Amsterdam, Netherlands), 2013, Vol.79, p.S11-S11

2013

Link zum Volltext

Verfügbarkeit prüfen

P1.22-21 Tertiary Lymphoid Structure Predicts Disease Free Survival in Patients with Resected Lung Adenocarcinoma Harboring Sensitizing EGFR Mutations

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S254-S255

2023

Link zum Volltext

Verfügbarkeit prüfen

TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer

Annals of oncology, 2020-04, Vol.31 (4), p.507-516

2020

Link zum Volltext

Verfügbarkeit prüfen

Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial

Annals of oncology, 2017-02, Vol.28 (2), p.270-277

2017

Link zum Volltext

Verfügbarkeit prüfen

Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS

Annals of oncology, 2019-02, Vol.30 (2), p.171-210

2019

Link zum Volltext

Verfügbarkeit prüfen

CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials

Annals of oncology, 2018-03, Vol.29 (3), p.687-693

2018

Link zum Volltext

Verfügbarkeit prüfen

Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials

Annals of oncology, 2016-11, Vol.27 (11), p.2103-2110

2016

Link zum Volltext

Verfügbarkeit prüfen

319O ALTA-3: A randomized trial of brigatinib (BRG) vs alectinib (ALC) in crizotinib (CRZ)-refractory advanced ALK+ NSCLC

Annals of oncology, 2022-11, Vol.33, p.S1564-S1564

2022

Link zum Volltext

Verfügbarkeit prüfen

384P Prevalence of fibroblast growth factor receptor 2b (FGFR2b) protein overexpression in squamous non-small cell lung cancer (sqNSCLC)

Annals of oncology, 2022-11, Vol.33, p.S1591

2022

Link zum Volltext

Verfügbarkeit prüfen

Treatment of NSCLC Patients with EGFR Mutation

Annals of oncology, 2012-10, Vol.23, p.xi29

Yang, J.C.-H.

2012

Link zum Volltext

Verfügbarkeit prüfen

1507TiP Phase Ib multicenter study of trastuzumab deruxtecan (T-DXd) and immunotherapy with or without chemotherapy in first-line treatment of patients (pts) with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) and HER2 overexpression (OE): DESTINY-Lung03

Annals of oncology, 2023-10, Vol.34, p.S848-S849

2023

Link zum Volltext

Verfügbarkeit prüfen

514MO Acquired mechanisms of resistance to first-line (1L) osimertinib with or without platinum-based chemotherapy (CT) in EGFR-mutated (EGFRm) advanced NSCLC: Preliminary data from FLAURA2

Annals of oncology, 2023-11, Vol.34, p.S1669-S1670

2023

Link zum Volltext

Verfügbarkeit prüfen

185TiP A phase Ib dose-escalation study evaluating trastuzumab deruxtecan (T-DXd) and durvalumab in combination with chemotherapy as first-line treatment in patients with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) and HER2 overexpression (DESTINY-Lung03)

Journal of thoracic oncology, 2021-04, Vol.16 (4), p.S798-S798

2021

Link zum Volltext

Verfügbarkeit prüfen

INSIGHT 2: Tepotinib plus osimertinib in patients with EGFR-mutant NSCLC having acquired resistance to EGFR TKIs due to MET-amplification: A phase II trial in progress study

Annals of oncology, 2019-11, Vol.30, p.ix181

2019

Link zum Volltext

Verfügbarkeit prüfen

EP08.02-127 Resistance Mechanisms to Osimertinib in Advanced EGFR-mutated NSCLC: A Single Institution Prospective Cohort Study

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S463

2022

Link zum Volltext

Verfügbarkeit prüfen

552P TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in Asian patients (pts) with previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)

Annals of oncology, 2023-11, Vol.34, p.S1684-S1685

2023

Link zum Volltext

Verfügbarkeit prüfen

LBA10 Amivantamab plus lazertinib vs osimertinib as first-line treatment among Asian patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): MARIPOSA subgroup analysis

Annals of oncology, 2023-11, Vol.34, p.S1661

2023

Link zum Volltext

Verfügbarkeit prüfen

395P Afatinib in Asian and non-Asian patients (pts) with EGFR mutation positive (EGFRm+) NSCLC harboring major uncommon mutations

Annals of oncology, 2020-11, Vol.31, p.S1396-S1396

2020

Link zum Volltext

Verfügbarkeit prüfen

321MO Tepotinib in patients with MET exon 14 (METex14) skipping NSCLC: Results from all Asian patients in VISION

Annals of oncology, 2022-11, Vol.33, p.S1565-S1565

2022

Link zum Volltext

Verfügbarkeit prüfen

1348P Management of paresthesia in patients treated with lazertinib: Integrated analysis of LASER201 and LASER301 studies

Annals of oncology, 2023-10, Vol.34, p.S776-S776

2023

Link zum Volltext

Verfügbarkeit prüfen

29P Real-world data of atezolizumab in combination with bevacizumab, and platinum-based chemotherapy for EGFR-mutant metastatic non-small cell lung cancer patients after failure of EGFR tyrosine kinase inhibitors

Journal of thoracic oncology, 2023-04, Vol.18 (4), p.S57

2023

Link zum Volltext

Verfügbarkeit prüfen

P2.11-02 Tepotinib in Asian Patients with MET exon 14 Skipping Non-small Cell Lung Cancer (NSCLC) in Long-term Follow-up From VISION

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S360

2023

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 128

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(128)
Mit Volltextzugriff
(128)

Publikationsform

Artikel
(128)

Sprache

Englisch
(128)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(14)
Life Sciences & Biomedicine
(12)
Oncology
(12)
Humans
(11)
Female
(6)
Male
(6)
Erbb Receptors - Genetics
(5)
Lung Neoplasms - Drug Therapy
(5)
Lung Neoplasms - Genetics
(5)
Nsclc
(5)
Aged
(4)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(4)
Carcinoma, Non-Small-Cell Lung - Genetics
(4)
Lung Neoplasms - Pathology
(4)
Middle Aged
(4)
Mutation
(4)
Original Research
(4)
Adult
(3)
Afatinib
(3)
Antineoplastic Agents - Therapeutic Use
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Annals Of Oncology
(95)
Journal Of Thoracic Oncology
(23)
Esmo Open
(6)
International Journal Of Production Research
(2)
European Journal Of Cancer
(1)
Lung Cancer
(1)

1 weiteren anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Overview of current systemic management of EGFR-mutant NSCLC

LBA1_PR Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts

P0066 A randomised phase 3 study comparing first-line pemetrexed plus cisplatin followed by gefitinib as maintenance with gefitinib monotherapy in east Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer

32 LUX-Lung 3: Symptom and health-related quality of life results from a randomized phase III study in 1st-line advanced NSCLC patients harbouring EGFR mutations

P1.22-21 Tertiary Lymphoid Structure Predicts Disease Free Survival in Patients with Resected Lung Adenocarcinoma Harboring Sensitizing EGFR Mutations

TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer

Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial

Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS

CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials

Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials

319O ALTA-3: A randomized trial of brigatinib (BRG) vs alectinib (ALC) in crizotinib (CRZ)-refractory advanced ALK+ NSCLC

384P Prevalence of fibroblast growth factor receptor 2b (FGFR2b) protein overexpression in squamous non-small cell lung cancer (sqNSCLC)

Treatment of NSCLC Patients with EGFR Mutation

1507TiP Phase Ib multicenter study of trastuzumab deruxtecan (T-DXd) and immunotherapy with or without chemotherapy in first-line treatment of patients (pts) with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) and HER2 overexpression (OE): DESTINY-Lung03

514MO Acquired mechanisms of resistance to first-line (1L) osimertinib with or without platinum-based chemotherapy (CT) in EGFR-mutated (EGFRm) advanced NSCLC: Preliminary data from FLAURA2

185TiP A phase Ib dose-escalation study evaluating trastuzumab deruxtecan (T-DXd) and durvalumab in combination with chemotherapy as first-line treatment in patients with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) and HER2 overexpression (DESTINY-Lung03)

INSIGHT 2: Tepotinib plus osimertinib in patients with EGFR-mutant NSCLC having acquired resistance to EGFR TKIs due to MET-amplification: A phase II trial in progress study

EP08.02-127 Resistance Mechanisms to Osimertinib in Advanced EGFR-mutated NSCLC: A Single Institution Prospective Cohort Study

552P TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in Asian patients (pts) with previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)

LBA10 Amivantamab plus lazertinib vs osimertinib as first-line treatment among Asian patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): MARIPOSA subgroup analysis

395P Afatinib in Asian and non-Asian patients (pts) with EGFR mutation positive (EGFRm+) NSCLC harboring major uncommon mutations

321MO Tepotinib in patients with MET exon 14 (METex14) skipping NSCLC: Results from all Asian patients in VISION

1348P Management of paresthesia in patients treated with lazertinib: Integrated analysis of LASER201 and LASER301 studies

29P Real-world data of atezolizumab in combination with bevacizumab, and platinum-based chemotherapy for EGFR-mutant metastatic non-small cell lung cancer patients after failure of EGFR tyrosine kinase inhibitors

P2.11-02 Tepotinib in Asian Patients with MET exon 14 Skipping Non-small Cell Lung Cancer (NSCLC) in Long-term Follow-up From VISION

Suchergebnisse filtern